市場調查報告書
商品編碼
934336

額顳葉型失智症 (FTD):流行病學的預測(到2030年)

Frontotemporal Dementia (FTD) - Epidemiology Forecast to 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球主要國家 - 美國,歐洲主要5個國家 (EU5:法國·德國·義大利·西班牙·英國) 、日本 - 的額顳葉型失智症 (FTD)疫情趨勢與今後的預測分析。

第1章 主要考察

第2章 額顳葉型失智症 (FTD)的概要

第3章 額顳葉型失智症 (FTD)的SWOT分析

第4章 疾病的背景和概要

  • 簡介
  • FTD的分期與症狀
  • 原因
  • 病理生理學
  • TDP-43蛋白病
  • 疾病的進展
  • 遺傳的趨勢
  • 關聯的額顳葉型失智症症候群
  • 診斷

第5章 流行病學和患者人口

  • 主要調查結果
  • 額顳葉型失智症(FTD)的患病者·患者總數 (主要7個國家的情況)
  • 流行病學分析的前提條件與根據 (主要7個國家的情況)

第6章 FTD:各國流行病學的趨勢

  • 美國
    • FTD的受診完畢患病人數
    • FTD的受診完畢患病人數:各類型
    • 各類型的FTD的一般案例
    • 原發性·進行性失語症的發病數量:各子類型
    • FTD相關的突然變異
  • 歐洲主要5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第7章 疾病的治療和管理

  • FTD的生物標記
  • 病人旅程 (患者的受診·行動途徑)

第8章 未滿足需求

第9章 案例研究

  • 通過病例報告探索額顳葉癡呆
  • 行為變量FTD表現出冷漠:美國的案例討論

第10章 附錄

第11章 DelveInsight的服務內容

第12章 免責聲明

第13章 關於:DelveInsight

目錄
Product Code: DIEI0421

DelveInsight's 'Frontotemporal Dementia (FTD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Frontotemporal Dementia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Frontotemporal Dementia (FTD) Understanding

Frontotemporal Dementia (FTD), is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. It is considered the third most common form of dementia following Alzheimer's disease (AD) and dementia with Lewy bodies. It is a cluster of syndromes that result from degeneration of the frontal and temporal lobes, and is subdivided into two categories that are unique in respect to their predominating presentations; namely, the behavioral subtype that accounts for about half of FTD cases, and the language subtype.

Frontotemporal Dementia Epidemiology Perspective by DelveInsight

The Frontotemporal Dementia (FTD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Frontotemporal Dementia are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Frontotemporal Dementia Detailed Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of FTD, Prevalent Cases of FTD by types, Subtype specific cases of Primary Progressive Apahasia and Mutations associated with FTD) scenario of Frontotemporal Dementia (FTD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

The DelveInsight FTD report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The report covers detailed overview of Frontotemporal Dementia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Frontotemporal Dementia (FTD) Report and Model provide an overview of the risk factors and global trends of FTD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides the insight about the historical and forecasted patient pool of Frontotemporal Dementia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Diagnosed Prevalent cases of FTD, Prevalent Cases of FTD by types, Subtype specific cases of Primary Progressive Apahasia and Mutations associated with FTD in 7MM

Report Highlights:

  • 11 Years Forecast
  • 7MM Coverage
  • Total Diagnosed Prevalent Cases of Frontotemporal Dementia
  • Prevalent Cases according to segmentation: Diagnosed cases of FTD, Prevalent cases of FTD by types, Subtype specific cases of Primary Progressive Apahasia, Mutations associated with FTD

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Frontotemporal Dementia?
  • What are the key findings pertaining to the Frontotemporal Dementia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2020-2030)?
  • What would be the total number of patients of Frontotemporal Dementia across the 7MM during the forecast period (2020-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2020-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2030)?
  • What is the disease risk, burden and unmet needs of Frontotemporal Dementia?
  • What are the currently available treatments of Frontotemporal Dementia?

Reasons to buy:

The Frontotemporal Dementia Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Frontotemporal Dementia market
  • Quantify patient populations in the global Frontotemporal Dementia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the target populations that present the best opportunities for Frontotemporal Dementia therapeutics in each of the markets covered
  • Understand the magnitude of Frontotemporal Dementia population by its types and mutations
  • The Frontotemporal Dementia epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Frontotemporal Dementia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Assessing the correct numbers for FTD is itself a challenge because the numbers available are estimates and even the organisations specific for FTD also are not sure about the exact burden of the disease in terms of the patient number.

There are handful of studies that estimate the epidemiology of FTD in the seven major markets. The study published by Knopman et al. is still considered as the landmark study and till date is quoted by many of the authors in their respective studies. The study reported the prevalence of FTD in 45-64-year-old age group as 15 to 22 per 100,000.

Similarly, the information quoted by the Association for Frontotemporal Degeneration (AFTD) which is a national 501(c)(3) non-profit dedicated to bringing about a world with compassionate care, effective support, and a future free of frontotemporal degeneration also point to a similar direction. The organisation quotes that the prevalence of FTD in the United States is estimated to be between 4-15 cases per 100,000

Table of Contents

1. Key Insights

2. Executive Summary of Frontotemporal Dementia

3. SWOT Analysis for Frontotemporal Dementia

4. Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Stages and Symptoms of FTD
  • 4.3. Causes
  • 4.4. Pathophysiology
  • 4.5. TDP 43 proteinopathy
  • 4.6. Disease progression
  • 4.7. Genetics
  • 4.8. Related Frontotemporal Dementia Syndromes
  • 4.9. Diagnosis

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. 7MM Total Prevalent Patient Population of Frontotemporal Dementia (FTD)
  • 5.3. 7MM - Epidemiology Assumptions and Rationale

6. Country-wise Epidemiology of FTD

  • 6.1. The United States
    • 6.1.1. Diagnosed Prevalent cases of FTD
    • 6.1.2. Prevalent cases of FTD by type
    • 6.1.3. Subtype- specific cases of Primary Progressive Aphasia in the United States
    • 6.1.4. Mutations associated with FTD in the United States
  • 6.2. EU-5
    • 6.2.1. Germany
      • 6.2.1.1. Diagnosed Prevalent cases of FTD
      • 6.2.1.2. Prevalent cases of FTD by type
      • 6.2.1.3. Subtype- specific cases of Primary Progressive Aphasia in Germany
      • 6.2.1.4. Mutations associated with FTD in Germany
    • 6.2.2. France
      • 6.2.2.1. Diagnosed Prevalent cases of FTD
      • 6.2.2.2. Prevalent cases of FTD by type
      • 6.2.2.3. Subtype- specific cases of Primary Progressive Aphasia in France
      • 6.2.2.4. Mutations associated with FTD in France
    • 6.2.3. Italy
      • 6.2.3.1. Diagnosed Prevalent cases of FTD
      • 6.2.3.2. Prevalent cases of FTD by type
      • 6.2.3.3. Subtype- specific cases of Primary Progressive Aphasia in Italy
      • 6.2.3.4. Mutations associated with FTD in Italy
    • 6.2.4. Spain
      • 6.2.4.1. Diagnosed Prevalent cases of FTD
      • 6.2.4.2. Prevalent cases of FTD by type
      • 6.2.4.3. Subtype- specific cases of Primary Progressive Aphasia in Spain
      • 6.2.4.4. Mutations associated with FTD in Spain
    • 6.2.5. The United Kingdom
      • 6.2.5.1. Diagnosed Prevalent cases of FTD
      • 6.2.5.2. Prevalent cases of FTD by type
      • 6.2.5.3. Subtype- specific cases of Primary Progressive Aphasia in The United Kingdom
      • 6.2.5.4. Mutations associated with FTD in The United Kingdom
    • 6.2.6. Japan
      • 6.2.6.1. Diagnosed Prevalent cases of FTD
      • 6.2.6.2. Prevalent cases of FTD by type
      • 6.2.6.3. Subtype- specific cases of Primary Progressive Aphasia in Japan
      • 6.2.6.4. Mutations associated with FTD in Japan

7. Treatment and Management

  • 7.1. Biomarkers for FTD
  • 7.2. Patient Journey

8. Unmet Needs

9. Case Studies

  • 9.1. Exploring frontotemporal dementia through a case report

Title: Exploring frontotemporal dementia through a case report: An emerging public health concern in disguise

  • 9.2. Behavioral variant FTD presenting with apathy: A case Discussion in the US

10. Appendix

  • 10.1. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables

  • Table 1: Summary of Frontotemporal Dementia (FTD) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Frontotemporal dementia neuroimaging correlations
  • Table 3: Total Prevalent Patient Population of FTD in 7MM (2017-2030)
  • Table 4: Diagnosed Prevalent Cases of FTD in the United States (2017-2030)
  • Table 5: Prevalent Cases of FTD by type in the United States (2017-2030)
  • Table 6: Subtype- specific cases of Primary Progressive Aphasia in the United States (2017-2030)
  • Table 7: Mutations associated with FTD in the United States (2017-2030)
  • Table 8: Diagnosed Prevalent Cases of FTD in Germany (2017-2030)
  • Table 9: Prevalent Cases of FTD by type in Germany (2017-2030)
  • Table 10: Subtype- specific cases of Primary Progressive Aphasia in Germany (2017-2030)
  • Table 11: Mutations associated with FTD in Germany (2017-2030)
  • Table 12: Diagnosed Prevalent Cases of FTD in France (2017-2030)
  • Table 13: Prevalent Cases of FTD by type in France (2017-2030)
  • Table 14: Subtype- specific cases of Primary Progressive Aphasia in France (2017-2030)
  • Table 15: Mutations associated with FTD in France (2017-2030)
  • Table 16: Diagnosed Prevalent Cases of FTD in Italy (2017-2030)
  • Table 17: Prevalent Cases of FTD by type in Italy (2017-2030)
  • Table 18: Subtype- specific cases of Primary Progressive Aphasia in Italy (2017-2030)
  • Table 19: Mutations associated with FTD in Italy (2017-2030)
  • Table 20: Diagnosed Prevalent Cases of FTD in Spain (2017-2030)
  • Table 21: Prevalent Cases of FTD by type in Spain (2017-2030)
  • Table 22: Subtype- specific cases of Primary Progressive Aphasia in Spain (2017-2030)
  • Table 23: Mutations associated with FTD in Spain (2017-2030)
  • Table 24: Diagnosed Prevalent Cases of FTD in The United Kingdom (2017-2030)
  • Table 25: Prevalent Cases of FTD by type in The United Kingdom (2017-2030)
  • Table 26: Subtype- specific cases of Primary Progressive Aphasia in The United Kingdom (2017-2030)
  • Table 27: Mutations associated with FTD in The United Kingdom (2017-2030)
  • Table 28: Diagnosed Prevalent Cases of FTD in Japan (2017-2030)
  • Table 29: Prevalent Cases of FTD by type in Japan (2017-2030)
  • Table 30: Subtype- specific cases of Primary Progressive Aphasia in Japan (2017-2030)
  • Table 31: Mutations associated with FTD in Japan (2017-2030)
  • Table 32: Diagnostic Markers in Current Use in FTD

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Types of Frontotemporal Dementia
  • Figure 3: Frontotemporal Dementia spectrum
  • Figure 4: Total Prevalent Patient Population of FTD in 7MM (2017-2030)
  • Figure 5: Diagnosed prevalent cases of FTD in the United States (2017-2030)
  • Figure 6: Prevalent Cases of FTD by type in the United States (2017-2030)
  • Figure 7: Subtype- specific cases of Primary Progressive Aphasia in the United States (2017-2030)
  • Figure 8: Mutations associated with FTD in the United States (2017-2030)
  • Figure 9: Diagnosed prevalent cases of FTD in Germany (2017-2030)
  • Figure 10: Prevalent Cases of FTD by type in Germany (2017-2030)
  • Figure 11: Subtype- specific cases of Primary Progressive Aphasia in Germany (2017-2030)
  • Figure 12: Mutations associated with FTD in Germany (2017-2030)
  • Figure 13: Diagnosed prevalent cases of FTD in France (2017-2030)
  • Figure 14: Prevalent Cases of FTD by type in France (2017-2030)
  • Figure 15: Subtype- specific cases of Primary Progressive Aphasia in France (2017-2030)
  • Figure 16: Mutations associated with FTD in France (2017-2030)
  • Figure 17: Diagnosed prevalent cases of FTD in Italy (2017-2030)
  • Figure 18: Prevalent Cases of FTD by type in Italy (2017-2030)
  • Figure 19: Subtype- specific cases of Primary Progressive Aphasia in Italy (2017-2030)
  • Figure 20: Mutations associated with FTD in Italy (2017-2030)
  • Figure 21: Diagnosed prevalent cases of FTD in Spain (2017-2030)
  • Figure 22: Prevalent Cases of FTD by type in Spain (2017-2030)
  • Figure 23: Subtype- specific cases of Primary Progressive Aphasia in Spain (2017-2030)
  • Figure 24: Mutations associated with FTD in Spain (2017-2030)
  • Figure 25: Diagnosed prevalent cases of FTD in The United Kingdom (2017-2030)
  • Figure 26: Prevalent Cases of FTD by type in The United Kingdom (2017-2030)
  • Figure 27: Subtype- specific cases of Primary Progressive Aphasia in The United Kingdom (2017-2030)
  • Figure 28: Mutations associated with FTD in The United Kingdom (2017-2030)
  • Figure 29: Diagnosed prevalent cases of FTD in Japan (2017-2030)
  • Figure 30: Prevalent Cases of FTD by type in Japan (2017-2030)
  • Figure 31: Subtype- specific cases of Primary Progressive Aphasia in Japan (2017-2030)
  • Figure 32: Mutations associated with FTD in Japan (2017-2030)
  • Figure 33: Unmet needs of FTD